InterMune, Inc. is a biotechnology company focused on developing and commercializing innovative therapies in pulmonology and hepatology.

Our pulmonology pipeline includes the fully enrolled Phase 3 “CAPACITY” program, evaluating pirfenidone for the treatment of patients with idiopathic pulmonary fibrosis, or IPF. IPF is a progressive disease, characterized by inflammation and scarring (fibrosis) of the lungs. InterMune also has a research program focused on small molecules for pulmonary disease.

In hepatology, we are focused on expanding treatment options for patients suffering from hepatitis C virus (HCV) infections. Our portfolio includes the HCV protease inhibitor compound ITMN-191, currently in Phase 1b development. We also have a second-generation HCV protease inhibitor research program and a research program evaluating a new target in hepatology.

InterMune additionally sells Actimmune® (interferon gamma-1b), approved for the treatment of severe, malignant osteopetrosis and chronic granulomatous disease.